Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
Immunotherapy approaches currently make their way into the clinics to improve the outcome of standard radiochemotherapy (RCT). The programed cell death receptor ligand 1 (PD-L1) is one possible target that, upon blockade, allows T cell-dependent antitumor immune responses to be executed. To date, it...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177615/ |